KETOF
SANTE
Identification
- Active ingredient (INN)
- KETOTIFENE** (SOUS FORME DE FUMARATE)
- Internal code
- 20 A 013
- Country of Origin
- Algeria
- Pharmaceutical form
- Oral Solution
- Prescription List
- Regulated (List II)
- Packaging
- flacon/100ml
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Indications
Ketottifin contributes to the prevention of asthma by improving breathing by reducing pulmonary swelling and aerobic infection in the lungs.
It should be noted that this drug is not used to control acute asthma seizures, where the drug needs to continue treatment for 2-3 months to begin its impact, and quick-impact drugs, such as salbutamol, cannot be replaced by this drug.
Associated Conditions
The drug is used with caution, under the supervision of a doctor, in the following cases: diabetes, especially in case of drinking, where it contains sugar. epilepsy, where the effective substance increases seizures and cramps.
Children under the age of 3.
Mechanism of Action
Kitotifen is one of the anti-hystmines that prevent the release of chemical agents that cause allergic reactions, such as hestatic symptoms, such as sneezes.